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I. THE ROLE AND IDENTIFICATION OF DONORS IN THE
TRANSMISSION OF CMV
Although epidemiologic data suggest that CMV is transmitted with blood
products, the identification of virus carriers has been elusive. Additionally, it has
been suggested that CMV may be transmitted in or with transplanted organs and
other tissues. In these latter instances it is uncertain whether CMV has been
transferred in endogenous cells or in circulating cells carried passively within the
organ. The location ofvirus and identification ofcarriers will have to precede the ap-
plication of techniques to eliminate these infections. Some specific suggested ques-
tions and topics for study are outlined below.
A. Blood
1. Do lymphocytes carry virus? Latent? Defective?
2. What characterizes the state ofCMV latency?
3. Do circulating macrophages or polymorphonuclear leucocytes carry virus?
4. Are circulating antigen-antibody complexes demonstrable?
5. What is the mechanism (or mechanisms) for activating latent virus?
6. Can techniques for the demonstration of CMV be applied to the identification
ofcarriers?
B. Kidney
1. Is CMV transmitted in renal (tubular) cells?
2. Is CMV transmitted in lymphocytes within the renal parenchyma or vascular
bed?
3. Does preexisting CMV infection (latent or active) influence the retention
and/or function ofthe graft?
4. Does the presence ofCMV in the donor (latent or active) influence course ofthe
homograft?
5. What is the impact ofCMV upon the host-immune response in general?
'These recommendations, summarized here by Drs. Ho and Lang, represent suggestions made by the
entire N.H.L.I. CMV contract group which in addition includes William L. Bayer, M.D., Milan Fiala,
M.D., Eli Gold, M.D., andJoseph S. Pagano, M.D., and their associates.
While these recommendations may seem like a "shopping list" for research grants and contracts, their
formulation represented the considered opinions of active, established investigators. They are included
here as a meansofdelineating unsolved problems in the field.
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C. Bone Marrow, Other
Similar questions apply to the study ofmarrow and other homografts.
II. CHARACTERIZATION OF THE RESPONSE OF THE RECIPIENT
TO CMV INFECTION
In this program the contractors concentrated most of their efforts upon problems
relevant to the transmission of CMV with blood products. Efforts were devoted to
the identification of carriers, elucidation of mechanisms pertaining to transmission
and activation, and epidemiologic features ofCMV infection. Less attention was de-
voted in the present program to the identification of specific CMV-associated syn-
dromes. Although the presence of CMV correlates with certain clinical syndromes,
the widespread occurrence of this virus in the absence of recognizable disease has
made difficult the general identification of the etiologic responsibilities of this virus.
At the same time the long-term effects of apparently asymptomatic persistent
and/or latent CMV infections remain to be assessed. Some questions appropriate for
investigation are posed.
A. Infection, Exogenous
Can primary and secondary CMV infections be identified and distinguished?
What is the role ofvarious virus strains in reinfection?
B. Infection, Reactivated
Can reactivated latent infections be distinguished from new CMV infections and
reinfections?
Can techniques (some of which were explored and developed by contractors) be
developed orimproved which will facilitate these distinctions?
C. Disease
What proportion ofCMV infections lead to disease(short-term or long-term)?
How do host factors (including genetic constitution) pertain to the response to
CMV infection?
III. THE PATHOGENESIS AND IMMUNOLOGICAL PARAMETERS OF
INFECTION AND DISEASE CAUSED BY CMV
Many of the problems related to CMV cannot be understood or solved without
fundamental studies on how and by what mechanism infection or disease is brought
about, and on the nature and efficacy ofthe immunologic response to such infection.
A related but separate issue is the nature of modifying influence of immunologic
disorders or manipulations on the susceptibility and resistance ofthe host. Suggested
studies may be subdivided as follows.
A. Mechanism ofTransmission
1. Transplacental infection.
2. Perinatal infection.
3. "Natural" infection in the child, adolescent or adult.
4. Transmission by blood and other foreign tissues.
While our contract program has concentrated on the hazards of blood and its
components and to a lesser extent on the kidney as a vehicle oftransmission ofCMV,
it becomes evident that whenever one implicates one of these factors, one must rule
out "usual" or "natural" means oftransmission. CMV is assumed to be transmitted
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in many ways, but the precise mechanism is not known in any particular mode. How
important is transmission by respiratory droplets, milk, venereal route, urine, stool,
or fomites?
B. Host Factors
1. Genetic constitution.
2. Socioeconomic background.
3. Age.
4. Sex.
5. Pregnancy.
To understand the natural history of CMV infection and disease, many host sus-
ceptibility factors have been suspected, and some data are available on each of the
host factors cited. We do not know how such factors would operate in different
modes of transmission. For example, while the pregnant woman has been reported to
have higher rates ofCMV cervical infection, is that limited to certain modes oftrans-
mission? Is she also more susceptible in general (e.g., to CMV transmitted blood)?
C. Role ofHumoral and Cell-Mediated Immunity
CMV is a herpes virus, and many ofour concepts regarding the development and
efficacy of acquired humoral and cellular immunity following CMV infection are
derived from what we know about other herpes viruses. For example, we assume that
acquired humoral immunity exists, but that it is not potent enough to preclude reacti-
vation or superinfection. We don't really know how effective specific antibodies are in
the host. In immunosuppressed patients the presence of antibodies may be more an
index of potential reactivation than of protection. Cell-mediated immunity has been
assumed to be operative and important, but most of the evidence is indirect and cir-
cumstantial. We don't know how long immunity lasts.
D. Mechanism ofPersistence, Latency, andReactivation
1. Site oflatency (organ, tissue, cell, and subcellular structure).
2. Mechanisms ofreactivation (immunosuppression, allograft reaction, etc.).
It is a truism that CMV produces chronic, persistent, and possibly latent infections
which are activated under certain conditions. This important property of the virus
should be studied at all levels, particularly in view of the rapid advances in the study
oflatency ofother herpes viruses. The nature and site ofinfection at the subcellular,
cellular, and host level and the mechanisms of reactivation at the cellular and host
level should be understood.
E. The ImmunologicalImplications ofCMVInfection
It is clear now that besides stimulating classical humoral and cell-mediated im-
munity following infection, this virus produces other profound immunological
changes in the host, and in turn immunological changes in the host produced by other
methods have a profound effect on CMV infection and disease.
1. Immunological effects ofCMV infection.
a. The effect ofCMV infection on specific and nonspecific immune mechanisms
such as humoral, cell-mediated immunity, interferon formation, etc.
b. Effect on resistance to other viral and nonviral infections.
c. Effects on other aspects of the host, such as the immunological response to
allograft and possibly noninfectious diseases.
2. Effects ofimmunosuppression on CMV infection.
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a. Immunosuppressive agents (cytotoxic agents, antilymphocyte serum,
steroids, etc.).
b. Physical agents (X-irradiation, etc.).
IV. METHODOLOGY
Progress in the field ofCMV research depends on advances in laboratory research
techniques and purely virological aspects of this agent. One such problem is the
identification of viral subtypes, if indeed they exist. Immunological methods should
be pursued, but they may be supplemented by newer methods such as nucleic acid
hybridization. An offshoot of this problem is the specificity of serologic tests. Areas
requiring special attention are listed.
A. Identification ofVirus Subtypes
B. Serological Methods
1. Sensitivity and specificity.
2. Identification ofspecific subtypes.
C. Improved Methods ofDetecting Infection
Detection ofantigen in circulation or in tissues, for example.
D. Methodsfor Detection ofLatent Virus
V. PREVENTION AND THERAPY
The contractors did not work specifically upon aspects of therapy, although some
studies were pertinent to preventive measures. It is not clear at present whether im-
munoprophylaxis is feasible in the case of an agent which may possess a multiplicity
of varients and which can establish persistent or latent infections. Studies of human
and murine CMV have implied that attenuation may be achieved by in vitro passage.
This "attenuation" may reflect the in vitro selection of defective-interfering CMV
which in turn raises questions about potential oncogenicity. Questions posed by the
contractors include:
A. Immunization
Can a killed CMV vaccine be developed?
Does CMV attenuation reflect the selection ofdefective virus?
Does the route ofinoculation influence the host response to CMV infection?
Does "attenuation" enhance CMV (experimental) oncogenicity?
B. Chemotherapy
Can chemotherapy alter the establishment oflatent or persistent CMV infections?
Are adenine arabinoside or phosphonoacetic acid applicable to the therapy of
CMV infections? To the eradication ofthe carrier state? Latent infections?
C. Immunotherapy
Is the use ofimmunologic adjuvants such as BCG or Corynebacterium parvum ap-
plicable to the elimination ofCMV persistence or latency?
D. Screening
Will the rapid recognition and identification ofCMV carriers permit their elimina-
tion from pools ofdonors (blood, kidney, marrow, etc.)? Is this appropriate? (See IB.)
Is it feasible?
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E. Interruption ofTransmission
IfCMV is demonstrated in specific cells, it would seem appropriate to seek means
to remove or eliminate these virus-carrier cells. For example, if leukocytes (?
lymphocytes) or macrophages harbor latent CMV and if antigenic interactions ac-
tivate these agents, the use of component transfusion might eliminate CMV from
blood products.